- The European Commission has granted a six-month extension to BRAVƎ
October 2024, Pamplona (Spain).
The European Commission has approved a six-month extension to the BRAV3 project in order to further explore its key areas of investigation. With this extension, the project which started the 1st of January of 2020 will ends the next 30th of June of 2025, allowing the consortium to continue their pioneering work and refine their findings, with the aim of providing more in-depth insights into potential treatments for cardiovascular diseases.
The extension, which was granted following a successful mid-term evaluation, will provide researchers with additional time to address new questions that have emerged during the study’s ongoing phases. It will also allow the team to enhance their experimental methodologies and analyze data with better precision.
Professor Felipe Prosper, the Coordinator of the project, expressed optimism about the extended timeline, stating, “The extra six months will enable us to complete several critical stages of our research that were identified as essential in the early phase of the project. We are excited to have the opportunity to expand the scope of our work and delve deeper into areas that promise to yield transformative results.”
The extended timeline is expected to lead to more refined conclusions and recommendations, potentially influencing both the academic field and real-world policy decisions.
The project, which is being carried out by 16 partners from six European countries, has garnered widespread attention due to its ambitious scope and potential to address some of the most pressing issues of our time. As the extended timeline unfolds, both the scientific community and the public will be closely watching for any breakthroughs or innovations that may emerge from this critical phase of the study.